Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.36 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2821886 | 0.89 | PTGS2 (0.41) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2821524 | 0.88 | PTGS2 (0.40) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2821147 | 0.85 | PTGS2 (0.38) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2820848 | 0.85 | HTR2B (0.41) | PTGS2TRPV1NTSR1PTGS1MCHR1 | |
| SCHEMBL2823191 | 0.84 | PTGS2 (0.37) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2825540 | 0.82 | ALDH1A1 (0.39) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2822428 | 0.82 | GPR119 (0.36) | NPC1RAB9APTGS2TRPV1GPR119 | |
| SCHEMBL2822518 | 0.81 | PTGS2 (0.37) | PTGS2PTGS1 | |
| SCHEMBL2821180 | 0.78 | IDO1 (0.42) | MEN1KMT2ANPC1MAPTRAB9A | |
| SCHEMBL2821061 | 0.77 | MAT2A (0.40) | MEN1KMT2ANPC1MAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | claimed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | claimed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | claimed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | claimed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | claimed |
| EP-1809605-B1 | QUINOLINES AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7576217-B2 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMAN-LA ROCHE INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-1809605-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. Hoffmann-Roche AG (CH) | 2007-07-25 | — | — | EP | disclosed |
| WO-2006048146-A1 | QUINOLINE AS ALLOSTERIC ENHANCERS OF THE GABA-B RECEPTORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-05-11 | — | — | WO | disclosed |
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | HOFFMANN-LA ROCHE INC. | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094754-A1 | Quinolines as allosteric enhancers of the GABAB receptors | GABRB1, GABRB2, GABRA1 | MEN1 2250/4885KMT2A 1319/4885NPC1 3410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.